Frelii Appoints Two New Members to its Scientific Advisory Board

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Frelii Inc. (OTCQB: FRLI) (Frelii or The Company) today announced that it has appointed two renowned physicians, Anthony R. Torres, M.D. and Susan H. Morelli M.D., to its Scientific Advisory Board.

The expertise, experience and guidance of Dr. Morelli and Dr. Torres will help Frelii accelerate and improve our pilot clinical trials, which will drive an increase in the speed of learning of our algorithms and AI platform, said Ian Jenkins, CEO of Frelii. We are thrilled to welcome these two incredible minds to the team as we address the challenges and opportunities of delivering practical and accurate whole-genome sequencing solutions to the market. Having Dr. Morelli and Dr. Torres on our Advisory Board is a significant validation of Frelii, the companys technology and its direction in the industry.

Dr. Torres received his M.D. degree at the University of Utah and completed his postdoctoral training as a Research Associate at the National Institutes of Health and as a resident at Yale University. He has been published in dozens of peer-reviewed journals for his work in protein chemistry, molecular biology, the genetics of autism and more. Dr. Torres has had an illustrious career not only in university research, but also in the biotechnology field. He also obtained seven patents for novel inventions in numerous areas.

Dr. Morelli is a neonatologist at Utah Valley Hospital and is affiliated with multiple hospitals in the area. She received her bachelors degree in mathematics from Harvard University and her medical degree from University of Connecticut School of Medicine. She is has been published in several journal articles and has been in practice for nearly 25 years. She has held the position of instructor at the Department of Pediatrics, Division of Medical Genetics at the University of Utah and she is board certified by the American Board of Pediatrics and the American Board of Medical Genetics.

These two individuals are joining the Frelii Inc. Scientific Advisory Board, which includes Dr. Shayne Morris, a molecular biologist and Dr. Hans Jenkins, the Chief Medical Officer of Frelii.

About Frelii Inc.

Frelii Inc. is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications. Its technology analyzes the most comprehensive markers (60,000,000+) on the market to date. Freliis technology generates accurate and profoundly valuable insight into DNA. It opens opportunities never before realized in health care, precision medicine, insurance, corporate wellness as well as personal health and risk identification. For more information, please visit www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

Follow Frelii online at:

Frelii Facebook Page https://www.facebook.com/livefrelii/ Frelii Twitter Feed @livefrelii Frelii Instagram Page @livefrelii Frelii LinkedIn Page linkedin.com/company/frelii/

Safe Harbor Statement:

This release contains certain forward-looking statements relating to the business of the Company. All statements, other than statements of historical fact included herein are forward-looking statements including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as believes, expects or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Companys actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Companys periodic reports that are filed with the Securities and Exchange Commission and available on its website (https://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Media Contact:
Tim Rush
[email protected]